Drug
Dapirolizumab Pegol
Dapirolizumab Pegol: highest development phase Phase 3, developed by UCB. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dapirolizumab pegol NCT04976322 | Phase 3 | Systemic Lupus Erythematosus |
Latest
No recent events.
Follow Dapirolizumab Pegol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.